05:22 PM EST, 01/07/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said late Tuesday the US Food and Drug Administration cleared the company's investigational new drug application for SGT-212 to treat Friedreich's ataxia.

The company expects to begin a phase 1b clinical trial of SGT-212 in H2 with study participants to be followed out to five years after receiving the treatment.

Friedreich's ataxia is a degenerative disease caused by inadequate levels of the frataxin protein.

Solid Biosciences ( SLDB ) shares rose 13% in after-hours activity.

Price: 4.44, Change: +0.52, Percent Change: +13.27